Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

AngioDynamics (ANGO) reported stronger-than-expected Q4 fiscal 2025 revenue and a narrower adjusted loss, driven by strong execution across its diversified medical device portfolio. Growth is primarily propelled by its NanoKnife system, benefiting from FDA clearance, increasing disposable sales, and upcoming reimbursement catalysts for prostate (2026) and pancreatic (2027) procedures, alongside robust performance from Auryon and AlphaVac. While the company projects 50% growth over the next year, profitability remains pressured by tariffs, and fiscal 2026 loss estimates have widened significantly from 6 cents to 30 cents per share, indicating potential headwinds despite operational strengths.

Analysis

AngioDynamics (ANGO) presents a mixed financial profile, characterized by strong operational execution offset by significant profitability headwinds. The company exceeded expectations in its fourth-quarter fiscal 2025 results, delivering a narrower-than-expected adjusted loss per share and robust revenue growth. This top-line momentum is driven by a diversified portfolio, with the Auryon system achieving its 16th consecutive quarter of double-digit growth and the NanoKnife system showing strength in recurring disposable sales, which grew 9.6% for the year. The long-term growth narrative is supported by critical upcoming catalysts, notably the expected assignment of CPT Category I reimbursement codes for NanoKnife prostate procedures in 2026 and pancreatic procedures in 2027. However, this growth potential is currently overshadowed by tangible pressures on profitability. Tariffs are a notable drag, reducing Med Tech margins from 62.1% to 59% in the recent quarter. More critically, the consensus estimate for the fiscal 2026 loss per share has widened substantially from 6 cents to 30 cents over the past 60 days, signaling deteriorating near-term earnings expectations despite a projected 7.9% rise in first-quarter revenue.

Key Decisions for Investors

• Given the contrast between strong product-level growth and deteriorating profitability estimates, a neutral or 'Hold' position appears prudent until the company demonstrates a clear path to improved margins.
• Investors should closely monitor the progress of key long-term catalysts, as the successful implementation of the NanoKnife CPT reimbursement code in 2026 represents a major potential inflection point for the stock's value.
• Pay close attention to upcoming quarterly results for any deviation from the fiscal 2026 adjusted EBITDA guidance of $3.0-$8.0 million, as the widening consensus loss estimate suggests the market is skeptical of near-term earnings power.